Patents

• Apparatus and Method for Measuring Augmented Osmotic Pressure in a Reference Cavity was granted in 2018 (2013 in the USA). This patent pertains to a device for monitoring changes in osmotic pressure in response to concentration changes of specific dissolved solute particles. The patent expires in 2030.
• Interstitial Fluid Osmotic Pressure Measuring Device System and Method was granted in 2011. This patent describes a sensor design aimed at improving signal amplitude, increasing the accuracy of subcutaneous glucose assessments, and enhancing sensor longevity and resistance to environmental interferences. It also allows for the measurement of other analytes in addition to glucose. The patent expires in 2038.
• Fluid Composition, Method for Preparing the Composition and Use was granted in 2024. This patent covers the modular chemical composition used in Lifecare’s miniaturized sensor technology. The active fluid enables glucose monitoring through osmotic pressure, improving sensor lifetime, measurement response symmetry, and sensitivity. This technology supports miniaturization and long-term continuous in vivo monitoring without patient discomfort or reduced quality of life. The patent expires in 2037.
• A new patent for conceptual chemistry composition including modular receptor molecules was filed in May 2024. The patent applicated relates to a new conceptual chemistry composition that includes modular receptor molecules for detecting a wide range of diseases or conditions. This chemistry invention comprises various receptors (cellular, biological, artificial, synthesized, oligonucleotides, inorganic receptor layers, etc.) designed to induce changes in osmotic pressure. The purpose of this invention is to identify and/or monitor diseases or conditions associated with acute or chronic disorders, such as cardiovascular disease, metabolic disorders, infections, immune diseases, among others, in addition to Lifecare’s primary focus on diabetes. This patent application signals Lifecare’s expansion beyond glucose monitoring, aiming to become a broader sensor company. While maintaining its core mission of providing better solutions for people with diabetes, this move aligns with Lifecare’s overarching goal of improving lives through medical technology. The patent filing underscores Lifecare’s ambition to leverage its platform technology for the identification and monitoring of a wide range of acute and chronic disorders.

While the above-mentioned patents form the backbone of Lifecare’s proprietary technology, RemovAid ‘s product was patented in 2020. The patent expires in 2036.